MetaCap

enGene Therapeutics (ENGN) vs Palisade Bio (PALI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Palisade Bio (PALI) has outperformed enGene Therapeutics (ENGN) over the past year, losing 60.6% versus a loss of 75.0%. Palisade Bio is the larger company by market cap ($150.7 million vs $116.6 million), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ENGN-75.00%PALI-60.57%
+83%-2%-87%
Nov 21, 20251 yearNov 20, 2026
ENGN-82.35%PALI-99.88%
+203%+44%-114%
Jan 31, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ENGN versus PALI key metrics
MetricENGNPALI
Share price$1.74$0.8399
Market cap$116.61M$150.74M
1-day change-1.14%-9.24%
YTD return-80.73%-64.26%
1-year return-75.00%-60.57%
5-year return—-99.95%
P/E ratio (TTM)—0.91
EPS (TTM)$-2.07$0.92
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)$-117.30M$-16.78M
52-week high$12.25$2.86
52-week low$1.40$0.8381
Distance from 52-week high-85.80%-70.63%
Analyst consensusbuystrong_buy
Avg. price target upside+146.55%+935.84%
Average volume1.12M3.19M
Shares outstanding67.02M179.28M
Employees8114
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PALI has outperformed ENGN by 14.4 percentage points over the past year.

About enGene Therapeutics

ENGN stock →

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees

About Palisade Bio

PALI stock →

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees

ENGN vs PALI FAQ

Which is bigger, enGene Therapeutics or Palisade Bio?

Palisade Bio (PALI) is larger, with a market capitalization of $150.74M compared with $116.61M for enGene Therapeutics (ENGN).

Which stock has performed better over the past year, ENGN or PALI?

PALI returned -60.57% over the past 12 months, compared with -75.00% for ENGN (price return, excluding dividends). Past performance does not predict future results.

Are enGene Therapeutics and Palisade Bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons